[
    "ess in various experiments.</p>The present invention thus provides various thioether peptide monomer and dimer molecules which bind or associate with the \u03b14\u03b27 integrin, e.g., in serum, SIF, or SGF, to disrupt or block binding between \u03b14\u03b27 and the MAdCAM ligand. Some peptide monomer or peptide subunits of the invention may be constructed solely of natural amino acids. Alternatively, the peptide monomer and dimer molecules may include non-natural amino acids including, but not limited to, modified amino acids and suitable aromatic acid groups, namely a 2-methylbenzoyl moiety. Modified amino acids include natural amino acids which have been chemically modified to include a group, groups, or chemical moiety not naturally present on the amino acid. The thioether peptide monomer and dimer molecules of the present invention may additionally include D-amino acids.</p>In certain embodiments, peptide dimer and monomer molecules of the present invention inhibit or reduce binding between between \u03b14\u03b27 and the MAdCAM ligand. In certain embodiments, a peptide of the present invention reduces binding of \u03b14\u03b27 and the MAdCAM ligand by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% as compared to a negative control peptide. Methods of determining binding are known in the art and described herein, and include ELISA assays, for example.</p>In certain embodiments, a peptide monomer or dimer molecule of the present invention has an IC50 of &lt;500 nM, &lt;250 nM, &lt;100 nM, &lt;50 nM, &lt;25 nM, or &lt;10 nM. Methods of determining activity are known in the art and include any of those described in the accompanying Examples.</p>Some antagonist thioether cyclized peptide monomer and dimer molecules have been shown to be gastrointestinal stable and provide high levels of specificity and affinity for the \u03b14\u03b27 integrin. Some implementations of the present invention provide a peptide monomer or dimer molecule comprising a half-life of greater than 180 minutes when exposed to simulated intestinal fluids (SIF). Some implementations further provide a thioether peptide monomer or dimer molecule comprising a half-life from approximately 1 minute to approximately 180 minutes. Similarly these peptides are stable to gastric environment under reduced conditions with half-life &gt;120 min when tested in DTT (Dithiothreitol) assay.</p>In certain embodiments, a peptide monomer or dimer molecule of the present invention has increased stability, increased gastrointestinal stability, or increased stability in stimulated intestinal fluid (SIF), as compared to a control peptide. In particular embodiments, a control peptide is a peptide having the identical or a highly related amino acid sequence (e.g., &gt;90% sequence identity) as the peptide monomer or dimer molecule, but which does not form a cyclized structure through a thioether bond. In some embodiments relating to dimer molecules, the control peptide is not dimerized",
    "e methods known in the art for determining degradation stability include the method described in Hawe et al J Pharm Sci, VOL. 101, NO. 3, 2012, p 895-913, incorporated herein in its entirety. Such methods are in some embodiments used to select potent peptide monomer or dimer molecules with enhanced shelf lifes.</p>In some embodiments, peptide dimer or monomer molecules of the present invention have increased redox stability as compared to a control peptide. Methods of determining redox stability are described herein.</p>In certain embodiments, peptide dimer or monomer molecules of the present invention inhibit or reduce \u03b14\u03b27-mediated inflammation. In related embodiments, peptide monomers or dimers of the present invention inhibit or reduce \u03b14\u03b27-mediated secretion of one or more cytokines. Methods of determining inhibition of cytokine secretion and inhibition of signaling molecules are known in the art.</p>In certain embodiments, peptide monomer or dimer molecules of the present invention demonstrate increased binding selectivity. In certain instances, peptide monomers or dimers of the present invention binds to \u03b14\u03b27 with at least a two-fold, three-fold, five-fold, or ten-fold greater affinity than the monomers or dimers bind to \u03b14\u03b21.</p>The peptide monomer or dimer molecules of the present invention demonstrate increased potency as a result of substituting various natural amino acyl residues with N-methylated analog residues. In particular embodiments, potency is measured as IC50 of binding to \u03b14\u03b27, e.g., determined as described herein, while in some embodiments, potency indicates functional activity, e.g., according to a cell adhesion assay as described herein or a PBMC assay described herein. For example, SEQ ID NOs.: 1-32 represent peptide monomer or subunit sequences that are substituted with N(alpha)methylated arginine.</p>In particular embodiments, any of these superior characteristics of the peptides of the present invention are measured as compared to a control peptide, e.g., a peptide shown in Table 8.</p>Referring now to FIG. 6 and Tables 5 and 7, charts are provided which include various data illustrating increased potency and/or stability for various non-limiting sample thioether peptide dimer molecules in accordance with the instant invention. Simulated Intestinal Fluid (SIF) Stability assays were performed for the majority of the dimer molecules. A selective sampling of these results is provided in FIG. 6. Indicated thioether peptides in FIG. 6 represent a non-limiting, representative group of dimer peptides with stability of greater than 180 minutes (half-life) in SIF. These thioether dimer compounds further represent IC50 values of less than 25 nM in ELISA as well as cell adhesion assays, further demonstrating their high selectivity for \u03b14\u03b27. For other peptides in FIG. 6, it is expected that they will have an IC50&lt;50 nM in \u03b14\u03b27 ELISA or cell adhesion assays.</p>Referring now to FIGS. 7 and 8 and Tables 4 and 6, charts are provided which includes various data illustrating increased potency for various non-limiting illustrative thioether peptide monomers in accordance with the instant invention. Potency assays were performed for all peptide molecules represented by SEQ ID NOs: 22 and 23 and additional peptides as shown. Selectivity assays (for \u03b14\u03b21) were performed for certain thioether peptides. A selective sampling of these results is provided in FIGS. 7 and 8. Improvements in potency for \u03b14\u03b27 were tested in both ELISA and cell adhesion assays.</p>According to the protocols discussed herein, applicant successfully synthesized and purified all of the integrin antagonist thioether peptides (e.g. peptide monomers and peptide dimers) represented by SEQ ID NOs: 22 to 24 and additional peptides shown in Tables 4-7 and FIGS. 6-8. The majority of these molecules were subjected to an \u03b14\u03b27-MAdCAM Competition ELISA assay, an \u03b14\u03b21-VCAM Competition ELISA assay, and an \u03b14\u03b27-MadCAM cell adhesion assay. Results are provided in Tables 6-7 and FIGS. 6-8. The thioether peptides shown in FIG. 7 represent a non-limiting, representative group of peptides with IC50 values less than 50 nM in ELISA assays. The peptides further represent IC50 values of less than 300 nM in cell adhesion assays. For other peptides with data not shown, it is expected that they will have an IC50&lt;50 nM in \u03b14\u03b27 ELISA or cell adhesion assays.</p>When Arg is replaced with N-Me-Arg, a significant improvement in potency for \u03b14\u03b27 was shown in both ELISA and cell adhesion assays. N(alpha)methylation further demonstrated increased molecular stability. One having skill in the art will appreciate that methylated isosteres of arginine may further demonstrate similar increases in potency and/or stability.</p>Referring now to FIGS. 6 and 8 charts are provided which include data illustrating increased stability for various non-limiting sample thioether peptide molecules in accordance with the instant invention. Simulated Intestinal Fluid (SIF) Stability assays were performed for the majority of the peptide molecules. A selective sampling of these results is provided in FIGS. 6 and 8. The thioether peptides in FIGS. 6 and 8 represent a non-limiting, representative group of peptides with stability of greater than 180 minutes (half-life) in SIF.</p>Methods of Manufacture and Enhancing Peptide Stability</p>The peptides (e.g. peptide monomers or peptide dimers) of the present invention may be synthesized by techniques that are known to those skilled in the art. Such techniques include the use of commercially available robotic protein synthesizers (e.g. Symphony multiplex peptide synthesizer from Protein Technologies). In some embodiments, novel peptide monomers or dimer subunits are synthesized and purified using techniques described herein.</p>Certain aspects of the present inv",
    "5 hours at RT using 200 ul per well. The Blocking Buffer was removed and either MAdCAM-1 or VCAM-1 at 400 ng/well in Blocking Buffer was added and the plate incubated overnight at 4 C (100 ul per well). The plate was washed two times with Blocking Buffer, and rinsed once with 200 ul Binding Media (DMEM phenol red free, 10 mM HEPES, 1\u00d7 Na pyruvate, 1\u00d7 Glutamine, and supplemented with 1 mM MnCl2 prior to use). To prepare cells, approximately 25 million CD4+/CD45RO+ memory T cells were counted by trypan blue exclusion using a haemocytometer to determine viability and cell count. The cells were transferred to a 50 ml conical tube, and centrifuged at 1200 rpm for 10 minute. The media was aspirated and the cell pellet resuspended in 15 ml Binding Media. The cells were centrifuged again and resuspended in the appropriate amount of Binding Media to be used for assays (50 ul of cells per well at 2\u00d7 the final density). To each well, and equal volume (50 ul) of test compound was added and the plate was incubated for 1.5 hours at 37 C, 5% CO2. Each well was rinsed 3\u00d7 with 150 ul per well of Binding Media. CyQuant NF reagent was prepared as suggested by manufacturer), and 100 ul of CyQuant NF reagent was added per well. The plate was incubated at 37 C, 5% CO2, for 45 minutes. The plate was protected from light by using black adhesive seals. Fluorescence intensity was measured using a Molecular Devices Gemini EM Fluorescent Plate Reader (Ex 485/Em530, Bottom Read, Reading Sensitivity=20). IC50 curves are generated using Graph Pad Prism and the curves analyzed using analyzed using a non-linear regression (four parameters) algorithm. The log (concentration) versus RFU (Ex485/Em530) was plotted to determine IC50 values.</p>\u03b14\u03b27-MAdCAM Cell Adhesion Assay</p>RPMI 8866 cells (Sigma #95041316) were cultured in RPMI 1640 HEPES medium (Invitrogen #22400-089) supplemented with 10% serum (Fetal Bovine Serum, Invitrogen #16140-071), 1 mM sodium pyruvate (Invitrogen #11360-070), 2 mM L-glutamine (Invitrogen #25030-081) and Penicillin-Streptomycin (Invitrogen #15140-122) at 100 units of penicillin and 100 \u03bcg of streptomycin per ml. The cells were washed two times in DMEM medium (ATCC #30-2002) supplemented with 0.1% BSA, 10 mM HEPES pH 7 and 1 mM MnCl2. The cells were re-suspended in supplemented DMEM medium at a density of 4\u00d710<sup>6 </sup>cells/ml.</p>A Nunc MaxiSorp plate was coated with rh MAdCAM-1/Fc Chimera (R&amp;D #6065-MC) at 200 ng per well in 50 ul per well in 1\u00d7PBS and incubated at 4\u00b0 C. overnight. The solution was then removed by shaking, blocked with 250 ul per well PBS containing 1% BSA, and incubated at 37\u00b0 C. for 1 hr. The solution was removed by shaking. Peptides were diluted by serial dilution in a final volume of 50 ul per well (2X concentration). To each well, 50 ul of cells (200,000 cells) were added and the plate was incubated at 37\u00b0 C., 5% CO<sub>2 </sub>for 30-45 min to allow cell adhesion. The wells were washed manually three times (100 ul per wash) with supplemented DMEM. After the final wash, 100 ul/well of supplemented DMEM and 10 ul/well of MTT reagent (ATTC cat#30-1010K) were added. The plate was incubated at 37\u00b0 C., 5% CO2 for 2-3 hrs until a purple precipi",
    " containing 1% BSA, and incubated at 37\u00b0 C. for 1 hr. The solution was removed by shaking. Peptides were diluted by serial dilution in a final volume of 50 ul per well (2\u00d7 concentration). To each well, 50 ul of cells (200,000 cells) were added and the plate was incubated at 37\u00b0 C., 5% CO<sub>2 </sub>for 30-45 min to allow cell adhesion. The wells were washed manually three times (100 ul per wash) with supplemented DMEM. After the final wash, 100 ul/well of supplemented DMEM and 10 ul/well of MTT reagent (ATTC cat#30-1010K) were added. The plate was incubated at 37\u00b0 C., 5% C02 for 2-3 hrs until a purple precipitate is visible. 100 ul of Detergent Reagent (ATTC cat#30-1010K) is added to each well. The plate was covered from the light, wrapped in Parafilm to prevent evaporation, and left overnight at room temperature in the dark. The plate was shaken for 5 min and the absorbance at 570 nm is measured. To calculate the dose response, the absorbance value of control wells not containing cells was subtracted from each test well.</p>The potency, selectivity and stability data for certain illustrative peptide monomers and dimers of the present invention are provided in Tables 6 and 7. These peptides have the structures shown in Tables 4 and 5, which may be identified by their SEQ ID NOs. Table 6 provides potency, selectivity and stability data for representative peptide monomers. Table 7 provides potency, selectivity and stability data for representative peptide dimers. For potency, IC50 values are shown as *&lt;25 nM **=25-100 nM, ***=100-1000 nM. Where data not shown, data was not determined, but is is expected that these peptides have an IC50 &lt;100 nM in \u03b14\u03b27 ELISA and/or cell assays.</p>TABLE 6Characterization of Illustrative Thioether Monomer PeptidesSEQELISAELISACell-AdhesionPBMCSIF (Porcine)SGF (Porcine)ID NOA4B7(nM)A4B1(nM)A4B7(nM)IC50(nM)(half-life, min)(Half -life, Min)49**&gt;100050***51**652&gt;100053***&gt;18054&gt;1000second55*******2556*******18657***&lt;2058&gt;100059***&lt;2060****&gt;18061*&gt;18062*&gt;18063*&gt;18064*17965***&gt;18066**&gt;18067*&lt;2068*&gt;18069****&gt;18070*&gt;18071**&gt;18072*&gt;18073*&gt;18074*&gt;18075*&gt;18076*&gt;18077*8878*7879*80***81******82****83*84*85*86*87*88***89****90*91****92***93***94****&gt;18095****&gt;18096****2697******&gt;180, &gt;180&gt;18098*********&gt;300&gt;18099*100***101*******102***103*104***105*106***107***108***109*110***111&gt;1000112&gt;1000113***114*****&gt;180115*116***117***118***119***120***121***122***123**124**125****&gt;180126**&gt;180127**128**129**130***131**132****&gt;180133****&gt;180134***&gt;180(428)135****136**137**138***139**140&gt;1000141&gt;1000142*</p>TABLE 7Characterization of Illustrative Thioether Peptide DimersSEQELISAELISACell-AdhesionCell AdhesionPBMCSIF (Porcine)SGF (Porcine)ID NOA4B7(nM)A4B1 (nM)A4B7 (nM)A4B1 (nM)IC50 (nM)(half-life, min)(Half-life, Min)143*&gt;1000***144*&gt;1000&gt;1000\u2002&lt;20145*****146****\u2002&lt;20147&gt;1000148&gt;1000149&gt;1000\u2002&lt;20150****&gt;100,000&gt;180, &gt;180,&gt;180&gt;300151****&gt;180152****&gt;100,000&gt;180&gt;60153****&gt;180 (275)154****&gt;100,000\u2002&lt;20155*******&gt;180, &gt;300&gt;180156****&gt;100,000&gt;180157*****\u2002&lt;20158*****&gt;100,000&gt;180159****&gt;100,000&gt;180&gt;180160**&gt;180&gt;60161****&gt;100,000&gt;180162***&gt;180163*&gt;180164****&gt;100,000&gt;180&gt;60165****&gt;100,000&gt;180&gt;60166****\u200330167****&gt;100,000\u2002&lt;20168****&gt;100,000169*****&gt;100,000&gt;180, &gt;180&gt;180170*171*172&gt;1000173**174*175*176*177*178*****&gt;1000&gt;180(375),&gt;180&gt;180(266), &gt;180179***180***181&gt;1000182**183**184*****&gt;100,000**&gt;180, &gt;180,&gt;180&gt;180185**186**187**188&gt;1000189&gt;1000190*191*&gt;100,000192*193*194****195*196*197*198*199*200*201*202***203***204*****&gt;100,000&gt;180&gt;180205***206&gt;1000207*****&gt;100,000&gt;180&gt;180208****&gt;100,000&gt;180 (312)&gt;180209*****&gt;100,000&gt;180210***211*\u2003\u20027212**213*<sup>\u2009</sup>&gt;180(419)214**215*216*&gt;180217**218*219*&gt;180, 407&gt;360220*&gt;180221**222**223**</p>TABLE 8Characterization of Illustrative Peptide MonomersRedoxSEQPeptideELISAELISACell-AdhesionSIF (Porcine)stabilityID NOsequence12345678910A4B7 (nM)A4B1(nM)A4B7(nM)(half-life, min)(DTT)385AcCRSDTLCGENH2972020590&lt;1 min~3 min386AcCRSDTLCNH296.828801221&lt;1 min~3 min</p>All of the above U.S"
]